Walgreens Boots Alliance (WBA) Stock Price, News & Analysis

-0.24 (-1.33%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
10.26 million shs
Average Volume
13.98 million shs
Market Capitalization
$15.36 billion
P/E Ratio
Dividend Yield
Price Target

Walgreens Boots Alliance MarketRank™ Stock Analysis

Analyst Rating
1.87 Rating Score
36.8% Upside
$24.36 Price Target
Short Interest
4.95% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.70mentions of Walgreens Boots Alliance in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$270,423 Bought Last Quarter
Proj. Earnings Growth
From $3.23 to $3.13 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.54 out of 5 stars

Retail/Wholesale Sector

22nd out of 199 stocks

Drug Stores & Proprietary Stores Industry

2nd out of 4 stocks

WBA stock logo

About Walgreens Boots Alliance Stock (NASDAQ:WBA)

Walgreens Boots Alliance Inc. is a world-renowned healthcare, pharmacy, and retailing company. Founded in 1901 by John Boot and Charles R. Walgreen, the company has grown to become a leader in the industry, operating in nine countries and providing access to healthcare services to millions of people around the world. Walgreens Boots Alliance operates through three main segments: U.S. Retail Pharmacy, International, and U.S. Healthcare.

The U.S. Retail Pharmacy segment includes the Walgreens business, which operates health and wellness services, retail drugstores, specialty and home delivery pharmacy services, and an equity method investment in AmerisourceBergen. Walgreens stores have locations in all 50 U.S. states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, offering access to consumer goods and services, pharmacy, photo department, and health and wellness services. Walgreens also operates online stores like Walgreens.com, Drugstore.com, VisionDirect.com, and Beauty.com.

The International segment consists of pharmacy-led health and beauty retail businesses outside the United States and a pharmaceutical wholesaling and distribution company in Germany. This segment includes the Boots brand, which has a history stretching back over 170 years in the United Kingdom, and stores in Ireland and Thailand with Boots franchise operations in the Middle East and Indonesia. The remainder of the division comprises Farmacias Ahumada (FASA) pharmacies in Chile and Benavides in Mexico. The Pharmaceutical Wholesale Division, including the Alliance Healthcare brand, supplied medicines and other healthcare products to more than 115,000  doctors, health centers,  pharmacies, and hospitals annually in eleven countries through 306 distribution centers. AmerisourceBergen purchased most of the Alliance Healthcare wholesale division in June 2021 for $6.275bn in cash.

The U.S. Healthcare segment is a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omnichannel experience across the care journey. This segment includes the operation of 334 VillageMD clinics, including 146 co-located clinics, 124 standalone clinics, and 64 affiliate clinics.

Walgreens Boots Alliance produces many brands, including Soltan and Botanics, Boots Pharmaceuticals, and Boots Laboratories, No. 7, that Alliance Boots and Walgreens sought to launch internationally following the first share purchase in 2012. These brands include the famous No. 7 beauty serums, developed in Nottingham, the UVA 5-star suncare protection by Soltan, and the Botanics range, developed in partnership with the Royal Botanic Gardens, Kew. Boots' brand range includes medicines, healthcare products, skincare, and many more. Walgreens also has a self-branded line of products called "Well at Walgreens."

For the fiscal year 2020, Walgreens Boots Alliance reported earnings of US$456 million. The reported revenue was US$139.5 billion, an increase of 2.5% over the previous fiscal cycle. As of 2022, Walgreens Boots Alliance is ranked #18 on the Fortune 500 rankings. The company pays a Quarterly dividend of $0.48, representing an annual dividend yield of 5.08%. Wall Street analysts consider Walgreens stock to be Undervalued. 

Walgreens Boots Alliance has 862,503,540 shares outstanding, and its market cap is currently $31.99B. The company’s EPS estimate is $1.12, and its most recent earnings report saw it beat expectations with an EPS of $1.16. Following the earnings report, the stock price went down -6.135%. Among the most significant hedge funds holding Walgreens Boots Alliance’s shares is Antipodes Partners Ltd., which owns shares valued at $58M.

Walgreens Boots Alliance is a global healthcare leader committed to providing high-quality services and products to its customers. The company’s innovative strategies have earned it a reputation as a reliable and reputable partner for healthcare providers and consumers. With its wide array of products and services, Walgreens Boots Alliance is well-positioned to continue growing and meeting the needs of its customers for years to come.

WBA Stock Price History

WBA Stock News Headlines

The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
This 4.8% Dividend Dog Has 31% Upside Potential
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Walgreens lost nearly $6 billion in its second quarter mainly due to a drop in value for the VillageMD clinic business it controls
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Walgreens Boots Alliance's NASDAQ: WBA efforts are paying off, although they still have work to do. The company's leaning toward efficiency and efforts to reinvigorate growth, sustain growth and improve profitability will drive shareholder value over the long term.
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Walgreens Boots Alliance is starting to emerge from the weeds but has more work to do. The stock trades at rock bottom, a deep value, and pays a high yield.
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
3 Reasons Walgreens Can See Upside (Rating Upgrade)
See More Headlines
Receive WBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Walgreens Boots Alliance and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/12 Dividend
Dividend Payable
Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Drug stores & proprietary stores
Drug Retail
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$139.08 billion
Cash Flow
$6.41 per share
Book Value
$17.61 per share


Free Float
Market Cap
$15.27 billion

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Stefano Pessina (Age 83)
    Executive Chairman of the Board
    Comp: $66.73k
  • Mr. Manmohan Mahajan (Age 44)
    Executive VP & Global CFO
    Comp: $1.16M
  • Ms. Ornella BarraMs. Ornella Barra (Age 71)
    Executive VP & COO of International
    Comp: $1.44M
  • Mr. Timothy C. WentworthMr. Timothy C. Wentworth (Age 64)
    CEO & Director
  • Mr. Todd D. Heckman (Age 50)
    Senior VP, Global Controller & Chief Accounting Officer
  • Dr. Neal Joseph Sample Ph.D. (Age 49)
    Executive VP & Chief Information Officer
  • Ms. Tiffany Ann Kanaga
    Vice President of Global Investor Relations
  • Mr. Matthew D'Ambrosio
    Senior VP and Global Chief Compliance & Ethics Officer
  • Ms. Elizabeth L. Burger (Age 53)
    Executive VP & Chief Human Resources Officer
  • Mr. Liyue Wu
    Head of M&A - Asia

Should I Buy Walgreens Boots Alliance Stock? WBA Pros and Cons Explained


Here are some ways that investors could benefit from investing in Walgreens Boots Alliance, Inc.:

  • Walgreens Boots Alliance, Inc. operates in the healthcare, pharmacy, and retail sectors, providing diversification in a stable industry.
  • The company has a strong presence in the United States, the United Kingdom, Germany, and internationally, offering geographic diversification.
  • Walgreens Boots Alliance, Inc. has a well-established brand and a long history dating back to 1909, indicating stability and experience in the market.
  • The U.S. Healthcare segment of the company, including VillageMD and Shields, provides exposure to the growing trend of value-based care and specialty pharmacy services.
  • Current stock price of Walgreens Boots Alliance, Inc. is favorable for value investors, potentially offering a good entry point.


Investors should be bearish about investing in Walgreens Boots Alliance, Inc. for these reasons:

  • Walgreens Boots Alliance, Inc. faces competition from online pharmacies and retail giants, impacting its market share and profitability.
  • The company operates in a highly regulated industry, subject to changes in healthcare policies and regulations that could affect its operations and financial performance.
  • Challenges related to the integration of acquisitions, such as the acquisition of Rite Aid stores, may pose risks to the company's growth strategy.
  • The drug stores and proprietary stores industry is highly competitive, with pressure on margins and pricing, affecting profitability.
  • Walgreens Boots Alliance, Inc. may face risks related to shifts in consumer behavior and preferences, impacting its retail and pharmacy business.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Walgreens Boots Alliance pros and cons to contact@marketbeat.com.

WBA Stock Analysis - Frequently Asked Questions

Should I buy or sell Walgreens Boots Alliance stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Walgreens Boots Alliance in the last year. There are currently 4 sell ratings, 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" WBA shares.
View WBA analyst ratings
or view top-rated stocks.

What is Walgreens Boots Alliance's stock price target for 2024?

15 Wall Street analysts have issued 1 year target prices for Walgreens Boots Alliance's shares. Their WBA share price targets range from $20.00 to $35.00. On average, they predict the company's stock price to reach $24.36 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for WBA
or view top-rated stocks among Wall Street analysts.

How have WBA shares performed in 2024?

Walgreens Boots Alliance's stock was trading at $26.11 at the beginning of 2024. Since then, WBA stock has decreased by 31.8% and is now trading at $17.81.
View the best growth stocks for 2024 here

When is Walgreens Boots Alliance's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024.
View our WBA earnings forecast

How were Walgreens Boots Alliance's earnings last quarter?

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) released its quarterly earnings data on Thursday, March, 28th. The pharmacy operator reported $1.20 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.38. The pharmacy operator earned $37.05 billion during the quarter, compared to analysts' expectations of $35.86 billion. Walgreens Boots Alliance had a negative net margin of 4.18% and a positive trailing twelve-month return on equity of 12.11%. The company's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.16 earnings per share.
Read the conference call transcript

How often does Walgreens Boots Alliance pay dividends? What is the dividend yield for Walgreens Boots Alliance?

Walgreens Boots Alliance declared a quarterly dividend on Wednesday, January 3rd. Stockholders of record on Tuesday, February 20th will be paid a dividend of $0.25 per share on Tuesday, March 12th. This represents a $1.00 annualized dividend and a yield of 5.61%. The ex-dividend date is Friday, February 16th.
Read our dividend analysis for WBA

Is Walgreens Boots Alliance a good dividend stock?

Walgreens Boots Alliance (NASDAQ:WBA) pays an annual dividend of $1.00 per share and currently has a dividend yield of 5.49%. WBA has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for WBA.

What guidance has Walgreens Boots Alliance issued on next quarter's earnings?

Walgreens Boots Alliance updated its FY 2024 earnings guidance on Thursday, March, 28th. The company provided earnings per share guidance of 3.200-3.350 for the period, compared to the consensus EPS estimate of 3.240. The company issued revenue guidance of -.

What is Stefano Pessina's approval rating as Walgreens Boots Alliance's CEO?

4,267 employees have rated Walgreens Boots Alliance Chief Executive Officer Stefano Pessina on Glassdoor.com. Stefano Pessina has an approval rating of 32% among the company's employees. This puts Stefano Pessina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Walgreens Boots Alliance own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Walgreens Boots Alliance investors own include AT&T (T), Intel (INTC), CVS Health (CVS), Johnson & Johnson (JNJ), Walt Disney (DIS), Cisco Systems (CSCO), AbbVie (ABBV), Verizon Communications (VZ), Pfizer (PFE) and Exxon Mobil (XOM).

Who are Walgreens Boots Alliance's major shareholders?

Walgreens Boots Alliance's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.30%), Raymond James & Associates (0.09%), Thompson Investment Management Inc. (0.06%), Sound Income Strategies LLC (0.05%), SteelPeak Wealth LLC (0.04%) and Kwmg LLC (0.04%). Insiders that own company stock include Inderpal S Bhandari, John Patrick Driscoll, Kevin M Ban, Manmohan Mahajan, Nancy M Schlichting, Nancy M Schlichting, Richard P Gates, Rosalind G Brewer, Timothy C Wentworth, Valerie B Jarrett and Walgreens Boots Alliance, Inc.
View institutional ownership trends

How do I buy shares of Walgreens Boots Alliance?

Shares of WBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Walgreens Boots Alliance have any subsidiaries?
The following companies are subsidiares of Walgreens Boots Alliance: Alliance Boots Holdings Limited, Alliance Healthcare Deutschland AG, Bond Drug Company of Illinois LLC, Boots Opticians Professional Services Limited, Boots Properties Limited, Boots Property Partnerships, Boots Retail (Ireland) Limited, Boots Retail (Thailand) Limited, Boots UK Limited, Duane Reade, Farmacias Benavides S.A.B. de C.V., Innovation Associates Inc, Liz Earle Beauty, Prime Therapeutics Specialty Pharmacy LLC, Shields Health Solutions, Sinopharm Holding GuoDa Drug Store Co., Superior Acquisitions Limited, Superior Holdings Limited, Superior Luxco 1 S.à r.l., Take Care Health Employer Solutions, The Boots Company PLC, WBA Acquisitions UK Holdco 7 Limited, WBA Acquisitions UK Topco Limited, WBA Financial LLC, WBA International Limited, WBA Investments Inc., WBA Luxembourg 6 S.à r.l., WBA Luxembourg 7 S.à.r.l., WBAD Holdings Limited, Walgreen Arizona Drug Co., Walgreen Co., Walgreen Eastern Co. Inc., Walgreen International S.à r.l., Walgreen Investments Luxembourg S.à r.l., Walgreen Louisiana Co. Inc., Walgreen of Puerto Rico Inc., Walgreens Boots Alliance (Hong Kong) Investments Limited, Walgreens Boots Alliance Holdings LLC, Walgreens Boots Alliance Limited, Walgreens Specialty Pharmacy LLC, and Waltrust Properties Inc..
Read More
This page (NASDAQ:WBA) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners